Stephen Peters to Quinolines
This is a "connection" page, showing publications Stephen Peters has written about Quinolines.
Connection Strength
0.532
-
Kaminsky DA, Wang LL, Bates JH, Thamrin C, Shade DM, Dixon AE, Wise RA, Peters S, Irvin CG. Fluctuation Analysis of Peak Expiratory Flow and Its Association with Treatment Failure in Asthma. Am J Respir Crit Care Med. 2017 Apr 15; 195(8):993-999.
Score: 0.150
-
Dahlin A, Litonjua A, Lima JJ, Tamari M, Kubo M, Irvin CG, Peters SP, Tantisira KG. Genome-Wide Association Study Identifies Novel Pharmacogenomic Loci For Therapeutic Response to Montelukast in Asthma. PLoS One. 2015; 10(6):e0129385.
Score: 0.132
-
Drummond MB, Peters SP, Castro M, Holbrook JT, Irvin CG, Smith LJ, Wise RA, Sugar EA. Risk factors for montelukast treatment failure in step-down therapy for controlled asthma. J Asthma. 2011 Dec; 48(10):1051-7.
Score: 0.103
-
Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ, Wise RA. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med. 2007 May 17; 356(20):2027-39.
Score: 0.075
-
Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, DiMango E, Fahy JV, Kraft M, Leone F, Lazarus SC, Lemanske RF, Martin RJ, Pesola GR, Peters SP, Sorkness CA, Szefler SJ, Israel E. Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med. 2007 Feb 01; 175(3):228-34.
Score: 0.072